Does correction of anemia slow the progression of chronic kidney disease?

被引：3

作者：

Singh, Ajay K. ^{[1
]}

机构：

[1] Brigham & Womens Hosp, Harvard Med Sch, Div Renal, Dialysis Serv, Boston, MA USA

来源：

NATURE CLINICAL PRACTICE NEPHROLOGY | 2007年 / 3卷 / 12期

关键词：

D O I：

10.1038/ncpneph0637

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Since the publication of the CHOIR and CREATE study results, tremendous attention has focused on the cardiovascular effects of anemia correction in patients with chronic kidney disease. Less publicized has been the finding of a potentially higher risk of progression to end-stage renal disease among patients assigned to a higher hemoglobin target. Ajay K Singh examines whether the sum of evidence indicates a harmful or a beneficial effect of anemia correction on the progression of kidney disease.

引用

页码：638 / 639

页数：2

共 12 条

[1] The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin [J].

Besarab, A ;

Bolton, WK ;

Browne, JK ;

Egrie, JC ;

Nissenson, AR ;

Okamoto, DM ;

Schwab, SJ ;

Goodkin, DA .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) :584-590

[2] Normalization of hemoglobin level in patients with chronic kidney disease and anemia [J].

Drueke, Tilman B. ;

Locatelli, Francesco ;

Clyne, Naomi ;

Eckardt, Kai-Uwe ;

Macdougall, Iain C. ;

Tsakiris, Dimitrios ;

Burger, Hans-Ulrich ;

Scherhag, Armin .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (20) :2071-2084

[3] ANEMIA LESSENS AND ITS PREVENTION WITH RECOMBINANT HUMAN ERYTHROPOIETIN WORSENS GLOMERULAR INJURY AND HYPERTENSION IN RATS WITH REDUCED RENAL MASS [J].

GARCIA, DL ;

ANDERSON, S ;

RENNKE, HG ;

BRENNER, BM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (16) :6142-6146

[4] Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trial [J].

Gouva, C ;

Nikolopoulos, P ;

Ioannidis, JPA ;

Siamopoulos, KC .

KIDNEY INTERNATIONAL, 2004, 66 (02) :753-760

[5]

LAFFERTY HM, 1991, J AM SOC NEPHROL, V1, P1180

[6] Darbepoetin alfa protects podocytes from apoptosis in vitro and in vivo [J].

Logar, C. M. ;

Brinkkoetter, P. T. ;

Krofft, R. D. ;

Pippin, J. W. ;

Shankland, S. J. .

KIDNEY INTERNATIONAL, 2007, 72 (04) :489-498

[7] The continuous erythropoietin receptor activator affects different pathways of diabetic renal injury [J].

Menne, Jan ;

Park, Joon-Keun ;

Shushakova, Nelli ;

Mengel, Michael ;

Meier, Matthias ;

Fliser, Danilo .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 18 (07) :2046-2053

[8] Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy [J].

Mohanram, A ;

Zhang, Z ;

Shahinfar, S ;

Keane, WF ;

Brenner, BM ;

Toto, RD .

KIDNEY INTERNATIONAL, 2004, 66 (03) :1131-1138

[9] Target level for hemoglobin correction in patients with diabetes and CKD: Primary results of the anemia correction in diabetes (ACORD) study [J].

Ritz, Eberhard ;

Laville, Maurice ;

Bilous, Rudy W. ;

O'Donoghue, Donal ;

Scherhag, Armin ;

Burger, Ulrich ;

De Alvaro, Fernando .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2007, 49 (02) :194-207

[10]

Rossert J, 2005, KIDNEY INT, V68, P76

← 1 2 →